Led By A World

Class Executive Team

Led By A World

Class Executive Team

Our team is dedicated to building a leading non-opioid analgesic and neurology specialty pharmaceutical company.

Joseph V. Pergolizzi, Jr., MD

Founder & Executive Chairman

Dr. Joseph V. Pergolizzi, Jr., MD is an internationally recognized thought leader in internal, perioperative and pain medicine, as well as critical and palliative care, pharmacology, drug development and regulatory affairs. An internationally recognized key opinion leader in pain medicine, Joe is a top development and regulatory consultant for blockbuster-branded analgesics, such as Nucynta, Cymbalta and Butrans. Joe is an experienced C-suite executive who brings an extensive professional network and background in global healthcare to Neumentum.

He is the co-founder of NEMA Research, Inc., a specialty CRO, a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics, and chairman of PAINWEEK and Consultant to National Pain Foundation Board of Directors. Joe is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He also formerly served as a part-time adjunct faculty member in the department of medicine at the Johns Hopkins University School of Medicine.


Taggart McGurrin

Chief Business Officer

Mr. Taggart (Tagg) McGurrin serves as the Chief Business Officer at Neumentum, Inc. He is responsible for corporate and financial strategy, corporate financing, accounting, legal, investor relations, and business development.

Tagg has an extensive business background and has held pharmaceutical, financial, accounting, legal, and government positions. He received both his bachelor and Master of Business Administration (MBA) degrees from the University of Scranton and his JD from Temple University’s James E. Beasley School of Law. He is a licensed Certified Public Accountant (CPA).


Frank Diana, PhD

Head of CMC/Manufacturing

Dr. Frank Diana is experienced in the areas of CMC, Pharmaceutical and Analytical Development. Frank had a 40-year career in the Pharmaceutical Industry working for Endo Pharmaceuticals, Johnson & Johnson and DuPont Pharmaceuticals mostly in Pharmaceutical Development, Technical Operations, and Quality. He obtained his PhD from St. John’s University in NY and is an adjunct professor in the RA/QA graduate program at Temple University’s School of Pharmacy teaching several courses including Global CMC Issues.


Sarah Howlett Faust

Sarah Faust

Chief Commercial Officer

Ms. Sarah Faust is a senior commercial leader in the pharmaceutical industry with U.S. and global experience. She has a proven track record of launching and growing multi-million to multi-billion dollar brands spanning the specialty, retail and institutional settings.

Sarah’s recent roles include leading all aspects of marketing at Depomed for the relaunch of Nucynta and Nucynta ER from acquisition, through repositioning, strategy development and oversight of tactical execution for launch. Prior to this, Sarah was Vice President of Sales and Marketing, for the specialty dermatology company, PharmaDerm. Here she managed the strategic refocusing of the Company’s portfolio and resource optimization to drive profitability, launched competitive action plans to defend the Company’s leading brand and led growth strategies to double revenues of another. Before PharmaDerm, Sarah held the position of Senior Vice President of Marketing for the specialty pharmaceutical company King Pharmaceuticals, where she oversaw the launch of the first abuse deterrent opioid, prepared launches for a portfolio of others and drove revenues of the Company’s existing pain and hospital based products. Sarah played a pivotal role in the transition of the PharmaDerm and King businesses following their acquisition by Sandoz and Pfizer respectively. Previously, Sarah led the global marketing team for Lovenox, the world’s leading low molecular weight heparin, where she established deep experience in the surgical and institutional settings.


Salma Lemtouni, MD, MPH

VP – Regulatory Affairs

Dr. Salma Lemtouni, in her 14 years at the Food and Drug Administration (FDA), acquired deep insight into FDA’s structured approach to Benefit-Risk assessment in drug regulatory decision-making, FDA’s approach to post-marketing safety evaluation and the impetus behind FDA’s policies and regulations.

At FDA’s Division of Cardiovascular and Renal Products, as a Senior reviewer, Salma guided pharmaceutical industry sponsors into developing sound regulatory plans that furthered drug development programs and achieved approval and marketing of much needed new therapies. At FDA’s Safe Use Initiative, she identified and investigated multiple post-marketing safety signals that led to regulatory action. Salma was given multiple awards for excellence in review and communication, for her contribution to redesigning New Drug Application review tools and for initiating internal and external collaborations that focused on the safety of FDA approved products.

Previous to her FDA tenure, as a medical officer at Medtronic, Salma initiated and established the clinical program for the premarket approval of SYNCRATM CRT-P (Cardiac Resynchronization Therapy in heart failure); and as a co-primary investigator, she managed 64 clinical trial centers in one of NIH’s largest studies, ALLHAT (Anti-hypertensive and Lipid Lowering to prevent Heart Attack Trial), the findings of which shaped the guidelines and changed the practice of medicine in the management of hypertension.


Robert Raffa

Robert B. Raffa, PhD

Chief Scientific Officer

Dr. Robert B. Raffa has devoted his professional career to pharmacology and understanding the balance between therapeutic utility and abuse potential of drugs. He was team co-leader for analgesics drug discovery at Johnson & Johnson, where he was involved in the elucidation of the mechanism-of- action of tramadol and the discovery of tramadol combinations. Bob has published over 300 peer-reviewed papers, is co-author or editor of several books on pharmacology and is a co-editor of the Journal of Clinical Pharmacy and Therapeutics. He taught at Temple University School of Pharmacy and is adjunct professor at the University of Arizona. He is a past president of the Mid-Atlantic Pharmacology Society, and he lectures and consults worldwide on analgesics and analgesic combinations.

Joseph V. Pergolizzi, Jr., MD

Founder & Executive Chairman

Dr. Joseph V. Pergolizzi, Jr., MD is an internationally recognized thought leader in internal, perioperative and pain medicine, as well as critical and palliative care, pharmacology, drug development and regulatory affairs. An internationally recognized key opinion leader in pain medicine, Joe is a top development and regulatory consultant for blockbuster-branded analgesics, such as Nucynta, Cymbalta and Butrans. Joe is an experienced C-suite executive who brings an extensive professional network and background in global healthcare to Neumentum.

He is the co-founder of NEMA Research, Inc., a specialty CRO, a former subcommittee member of the FDA SUI and SGE VAH Grant Review for Analgesics, and chairman of PAINWEEK and Consultant to National Pain Foundation Board of Directors. Joe is the former director of business development and financial affairs for the Johns Hopkins University School of Medicine Clinical Trials Unit. He also formerly served as a part-time adjunct faculty member in the department of medicine at the Johns Hopkins University School of Medicine.


Andrew Scott Blank

Director

Mr. Andrew Scott Blank, a third-generation Miamian, serves on the Executive Committee of the Greater Miami Jewish Federation and on the Board of BioCardia which has developed an individualized stem cell therapy including a unique ability to deliver stem cells directly to the heart muscle for the treatment of congestive heart failure. He has also served as the Chairman of the Florida Public Service Commission Nominating Council, Chairman of the Miami-Dade Community College Foundation (the largest community college in the US), Chairman of the Miami-Dade Community College Presidential Search Committee and was selected by Florida Trend Magazine as an “Up and Comer” Award Winner.

Andy serves as President of: National Brands, Inc., a family office which was, under the leadership of three generations of Blank family, the largest Anheuser-Busch beer distributor in the world; President of WareITis Technologies, LLC, (wareitis.com) which has developed the foremost enterprise level content management software suite; Archive America, (archiveamerica.com) a full-service, off-site records management company. Archive America is the largest family-owned document storage firm in the U.S. with locations in Miami, Tampa, Atlanta, Boston, Worcester, Chicago and Los Angeles; Seaboard Warehouse Terminals (seaboardwarehouse.com), Seaboard Chicago Terminals, and Seaboard Tampa Terminals. Seaboard provides third party logistics, including bonded warehousing, transportation & delivery, and contract storage services to manufacturers and sales organizations that require storage and distribution services for their products throughout the US.

Andy also serves as President of the Blank Family Foundation, (blankfamily.org) a Florida-based private family foundation which provides philanthropic support to a multitude of worthy charitable organizations.


August Moretti

Director

Mr. August Moretti joined Neumentum’s Board in April 2019. He is currently the CFO of 4D Molecular Technologies, a privately held gene therapy company. Augie has extensive operating and financial executive experience in all phases of company growth and funding, from early-stage development to product approval and commercialization. From 2012 to 2018 he was CFO of Assertio Therapeutics, a publicly held specialty pharmaceuticals company focused in pain and neurology, and from 2004 to 2011 CFO of Alexza Pharmaceuticals, a publicly held pharmaceutical company developing drug device combination products for pulmonary delivery of CNS drugs. From 2001 to 2004 he was CFO and General Counsel of Surromed, a privately held biotechnology company focused on proteomics. Prior to 2001 he was a partner of Heller Ehrman, an international law firm, where his practice included representation of life science companies on issues relating to public and private financings, mergers and acquisitions, corporate governance, disclosure and public reporting.

As CFO of Assertio, Alexza and Surromed he has raised over $1.5 billion in funding, including public and private issuance of equity, convertible debt and secured debt and monetization of royalty interests, has overseen several product acquisitions and has been responsible for 50 consecutive quarters of public company reporting.

Augie holds a B.A. in Economics from Princeton University and a J.D. from Harvard Law School and has taught Finance at UC Berkeley School of Business Administration.

Charles Argoff, MD

Professor in Neurology. Former NIH. Recognized expert in Chronic Pain.

Bill Loskota, MD, PhD

Distinguished Professor in Anesthesiology and Pharmacology. Pharmacy and Therapeutics expert.

William Schmidt, PhD

Seasoned Analgesic Drug Developer and Global Regulatory Expert

Eugene Viscusi, MD

Professor in Anesthesiology. Recognized innovator of acute analgesics.

Giustino Varrassi, MD

Professor in Anesthesiology. Former Chairman Anesthesiology. European authority on Ketorolac.

Paul White, MD, PhD

Distinguished Professor in Anesthesiology & Pharmacology. Former Chairman, Department Anesthesiology. Father of PCA & authority on ketorolac in US.